Checkpoint's (CKPT) cosibelimab Data Checks Right Boxes and Provides Further Validation of Potential - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Jennifer Kim reiterated an Overweight rating and $20.00 price target on Checkpoint Therapeutics (NASDAQ: CKPT) following recently ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
